In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price target of $86.00.
Sam Slutsky has given his Buy rating due to a combination of factors involving CG Oncology, Inc.’s promising clinical data and competitive positioning. The interim efficacy data from the Phase 3 BOND-003 study shows the company’s lead asset, cretosmogene, achieving a notable complete response rate in patients with high-risk non-muscle invasive bladder cancer. The durability of response, which is a critical measure in cancer treatment, also appears to be robust, with a significant percentage of patients maintaining their response for at least 12 months. Furthermore, the safety profile of cretosmogene is commendable, with the majority of treatment-related adverse events being non-severe and only a single patient discontinuing due to an unrelated adverse event.
Comparing the results of cretosmogene to Johnson & Johnson’s TAR-200 reveals competitive efficacy, though TAR-200 showed a higher any-time complete response rate. Importantly, cretosmogene demonstrated a better safety profile with no severe treatment-related adverse events, which could be a decisive factor for physician and patient preference. The anticipation that the agent with better durability of response might be favored first in the clinical setting further supports the positive outlook for CG Oncology’s product. Overall, Slutsky’s assessment likely factors in the promising efficacy, safety, and potential market positioning of cretosmogene against existing and emerging therapies.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 12.8% and a 47.68% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Astria Therapeutics, and Immunovant.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $75.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
CG Oncology, Inc. (CGON) Company Description:
Read More on CGON:
- Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
- CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- Five new option listings and one option delisting on March 12th
